| From Earlier: Forest Laboratories and Gedeon Richter Announce Positive Phase ... |
BenzingaBy Eddie Staley Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine, an investigational antipsychotic agent, in patients with acute mania associated ...
|
| Forest, Gedeon report positive Phase III bipolar I disorder trial data |
Pharmaceutical Business ReviewForest Laboratories and Gedeon Richter have reported positive results from Phase III trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder. The trial data showed that ...
|
| More strong data on Forest and Richter antipsychotic cariprazine |
The Pharma LetterUS drugmaker Forest Laboratories (NYSE: FRX) has announced positive preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I ...
|
| Strong quarter for Lundbeck but earnings to fall in 2012 |
Pharma TimesCipralex (escitalopram) slipped 1% to 1.43 billion kroner, while the US version of the product - sold by Forest Laboratories as Lexapro - climbed 11% to 581 million kroner. The Alzheimer's disease drug Ebixa (memantine) also increased 11% to 650 ...
|
| Positive Topline Phase 3 Results for Acute Mania Drug |
MedscapeFebruary 8, 2012 — Positive, topline results from a phase 3 clinical trial of the investigational antipsychotic cariprazine (RGH-188, Forest Laboratories Inc, Gedeon Richter Plc) show that the drug may be effective in treating acute mania associated ...
|
| Hungarian Stocks: Gedeon Richter, OTP Bank, Mol Move in Budapest |
BusinessWeekRichter and its partner Forest Laboratories Inc. said a Phase III clinical trial indicated that patients treated with the antipsychotic agent Cariprazine for acute manic episodes experienced “significant improvement.” OTP Bank Nyrt.
|
| Gedeon Richter, Forest tout promising results from antipsychotic Ph3 |
FierceBiotechInvestigators are reporting promising preliminary top-line results from a late-stage study of an experimental antipsychotic being studied by Hungary's Gedeon Richter and Forest Laboratories ($FRX). Shares of Gedeon Richter climbed a bit on the news.
|
